Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on September 15, 2021. The filing discloses a material event regarding a new underwritten public offering of common stock. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "LIFE".
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than periodic financial performance metrics such as revenue or operating profit. Key transaction figures include:
- Shares Issued: 9,375,000 shares of common stock.
- Offering Price: $8.00 per share.
- Estimated Gross Proceeds: Approximately $75.0 million (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters were granted a 30-day option to purchase up to an additional 1,406,250 shares.
- Underwriters: Piper Sandler & Co. and RBC Capital Markets, LLC.
- Expected Closing Date: September 20, 2021.
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the execution of a Purchase Agreement to raise capital through the issuance of new equity. This transaction represents a significant increase in the Company's share count and cash resources upon closing. No other material changes to operations or financial status are detailed in this specific filing.
Outlook, Risks, and Contingencies
The Company announced the pricing of the offering via a press release on September 16, 2021. The Purchase Agreement contains customary representations, warranties, covenants, and indemnification obligations. The filing notes that the representations were made solely for the benefit of the parties to the agreement and may be subject to limitations. The text does not provide specific management commentary on future operational outlook, risks, or contingencies beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriters exercised the option to purchase the additional 1,406,250 shares.
- Review the Company's most recent 10-Q or 10-K to assess current cash runway and burn rate in light of the new capital.
- Check for any subsequent filings regarding the use of proceeds from this offering.